Lanzamiento Enero 2027

Metaanálisis2022Financiación no declarada

Effects of almond on cardiometabolic outcomes in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Moosavian SP, Rahimlou M, Rezaei Kelishadi M, Moradi S, Jalili C

Phytotherapy research : PTR · 9 citas

Etiquetas de revisión

Financiación no declarada

Datos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.

Cómo se estudió

Diseño
Metaanálisis (indexado por PubMed)
Estudiado en
Personas
Resultado principal
Marcadores de salud y funcionamiento
Consumo medido con
No se indica

Quién lo pagó

Financiación
Financiación no declarada

Publicación

Publicado
2022-04-20 · Phytother Res · vol. 36 · número 5 · págs. 1839–1853
Editorial
Wiley
Citado
22 citas · más que el 67% de estudios similares · 1.0× el promedio de su campo
Referencias
93 trabajos
Acceso
De pago
Áreas de investigación
Nuts composition and effects · Nutritional Studies and Diet · Diabetes, Cardiovascular Risks, and Lipoproteins
Palabras clave
almond, type 2 diabetes, cardiometabolic outcomes, LDL cholesterol, cardiovascular risk, dietary intervention, nuts, fasting blood glucose, insulin, HbA1c, blood pressure, C-reactive protein, body weight
MeSH
humans, cardiovascular diseases, diabetes mellitus, type 2, blood glucose, cholesterol, ldl, randomized controlled trials as topic, prunus dulcis

5 autores

  • Seyedeh Parisa Moosavian🇮🇷Shiraz University of Medical Sciences
  • Mehran Rahimlou🇮🇷Zanjan University of Medical Sciences
  • Mahnaz Rezaei Kelishadi🇮🇷Isfahan University of Medical Sciences
  • Sajjad Moradi🇮🇷Kermanshah University of Medical Sciences
  • Cyrus Jalili🇮🇷 · autor de correspondenciaKermanshah University of Medical Sciences

Resumen

El texto original del estudio, en el idioma en que se publicó.

An enhanced risk for cardiovascular disease (CVD) still exists even when T2DM patients have tight control on blood sugar. Thus, identification of treatment approaches that address CVD risk factors may be useful for patients beyond the blood sugar management. Although emerging evidence suggests that nuts consumption have beneficial effects on cardiometabolic health, the effects of almond intake in patients with type 2 diabetes are still controversial. Therefore, our objective was to investigate the effect of almond on cardiometabolic outcomes in patients with T2DM through a systematic review and meta-analysis of available randomized controlled trials (RCTs). A systematic search was conducted in PubMed, Web of Science, Scopus, Embase, and Google Scholar to identify relevant RCTs up to March 2021. There was no language and time limitation. Weighted mean difference (WMD) was pooled using a random effects model. Heterogeneity, sensitivity analysis, and publication bias were reported using standard methods. Nine RCTs were included in the final analysis. Almond intake resulted in significant reduction in low-density lipoprotein cholesterol (LDL-C) (WMD: -5.28 mg/dL; 95% CI, -9.92, -0.64; p = .026) compared with the control group. This lowering effect of LDL-C was robust in subgroups with almond consumption >50 g/day, and baseline LDL-C level <130 mg/dL. However, the effect of almond on total cholesterol, triglycerides, high-density lipoprotein cholesterol, fasting plasma glucose, insulin, hemoglobin A1c, body mass index, weight, body fat, systolic and diastolic blood pressure, and CRP was not significant compared with the control group. In summary, the current meta-analysis indicated that almond consumption decreased LDL-C, and had no favorable effect on other cardiometabolic outcomes in patients with T2DM. However, further high-quality studies are needed to firmly establish the clinical efficacy of the almond.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.